Subtopic Deep Dive

T Regulatory Cell Therapy
Research Guide

What is T Regulatory Cell Therapy?

T Regulatory Cell Therapy uses ex vivo expanded CD4+CD25+FOXP3+ Tregs for adoptive transfer to induce antigen-specific immune tolerance in autoimmunity, transplantation, and GVHD.

This approach expands polyclonal or antigen-specific Tregs from patient blood for reinfusion. Key studies demonstrate safety and efficacy in refractory Crohn's disease (Desreumaux et al., 2012, 370 citations) and transplant tolerance (Edozie et al., 2014, 73 citations). Over 20 clinical and preclinical papers explore Treg homing via α4β7 integrin and stability against Th17 plasticity.

15
Curated Papers
3
Key Challenges

Why It Matters

Treg therapy enables targeted immunosuppression, reducing infection risks from broad drugs in IBD and autoimmunity (Desreumaux et al., 2012). In transplantation, it supports tolerance induction without chronic immunosuppression (Edozie et al., 2014). Alexander and Greco (2022) highlight its role in EBMT protocols for refractory autoimmune diseases, with 83 citations underscoring scalability for GVHD prevention.

Key Research Challenges

Treg Stability in Inflammation

Tregs lose FOXP3 expression and convert to Th17-like cells in cytokine-rich environments (Ueno, 2015). Globig et al. (2014, 122 citations) identified IFN-γ+IL-17+ CD4+ accumulation in active IBD, complicating Treg function. This plasticity hinders long-term therapy efficacy.

Gut Homing Efficiency

α4β7 and GPR15 mediate Treg homing to inflamed mucosa, but inhibitors like vedolizumab impair it (Sun et al., 2019, 37 citations; Fischer et al., 2015, 156 citations). Balancing effector and Treg trafficking remains critical for IBD. Neurath (2013, 300 citations) links this to mucosal healing targets.

Scalable Ex Vivo Expansion

Clinical-scale Treg production requires GMP protocols maintaining suppressive function (Esensten et al., 2018, 153 citations). Desreumaux et al. (2012) achieved antigen-specific expansion for Crohn's, but yields vary. Edozie et al. (2014) note challenges in antigen-specificity for transplants.

Essential Papers

1.

Safety and Efficacy of Antigen-Specific Regulatory T-Cell Therapy for Patients With Refractory Crohn's Disease

Pierre Desreumaux, Arnaud Foussat, Matthieu Allez et al. · 2012 · Gastroenterology · 370 citations

2.

New targets for mucosal healing and therapy in inflammatory bowel diseases

Markus F. Neurath · 2013 · Mucosal Immunology · 300 citations

3.

Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo

Anika Fischer, Sebastian Zundler, Raja Atreya et al. · 2015 · Gut · 156 citations

Objective Gut homing of lymphocytes via adhesion molecules has recently emerged as new target for therapy in IBDs. We aimed to analyse the in vivo homing of effector (Teff) and regulatory (Treg) T ...

4.

Regulatory T-cell therapy for autoimmune and autoinflammatory diseases: The next frontier

Jonathan H. Esensten, Yannick D. Müller, Jeffrey A. Bluestone et al. · 2018 · Journal of Allergy and Clinical Immunology · 153 citations

5.

Comprehensive Intestinal T Helper Cell Profiling Reveals Specific Accumulation of IFN-γ+IL-17+Coproducing CD4+ T Cells in Active Inflammatory Bowel Disease

Anna-Maria Globig, Nadine Hennecke, Bianca Martin et al. · 2014 · Inflammatory Bowel Diseases · 122 citations

Our results argue against the controversial TH1/TH2 or TH17/Treg paradigms. In contrast, they suggest that a subpopulation of TH17 cells sharing a TH1 signature may be specifically involved in inte...

7.

Th17 plasticity and its changes associated with inflammatory bowel disease

Aito Ueno · 2015 · World Journal of Gastroenterology · 77 citations

CD4 T helper (Th) cell differentiation into distinct T cell subsets is critical to the normal function of the immune system. Until recently, the paradigm held that naïve T cells differentiated into...

Reading Guide

Foundational Papers

Start with Desreumaux et al. (2012, 370 citations) for first-in-human antigen-specific Treg trial in Crohn's, then Edozie et al. (2014) for transplant protocols, and Neurath (2013, 300 citations) for mucosal targets.

Recent Advances

Study Esensten et al. (2018, 153 citations) for next-frontier review, Alexander and Greco (2022, 83 citations) for HSCT integration, and Sun et al. (2019) for integrin homing risks.

Core Methods

Ex vivo expansion (IL-2/rapamycin), antigen-specific pulsing (Desreumaux 2012), α4β7/GPR15 homing (Fischer 2015), stability assays against Th17 cytokines (Ueno 2015).

How PapersFlow Helps You Research T Regulatory Cell Therapy

Discover & Search

Research Agent uses searchPapers and exaSearch to find 250+ OpenAlex papers on 'Treg therapy Crohn's', revealing Desreumaux et al. (2012, 370 citations) as top hit. citationGraph traces downstream impacts to Esensten et al. (2018); findSimilarPapers links to Fischer et al. (2015) on homing.

Analyze & Verify

Analysis Agent applies readPaperContent to extract Treg expansion protocols from Desreumaux et al. (2012), then runPythonAnalysis on citation data for statistical trends in IBD trials (NumPy/pandas). verifyResponse with CoVe and GRADE grading confirms claims on stability (e.g., Ueno 2015 plasticity) against contradictions in Globig et al. (2014).

Synthesize & Write

Synthesis Agent detects gaps in Treg homing post-vedolizumab via contradiction flagging across Sun et al. (2019) and Neurath (2013). Writing Agent uses latexEditText, latexSyncCitations for protocol reviews, and latexCompile for figures; exportMermaid diagrams Th17/Treg plasticity pathways from Ueno (2015).

Use Cases

"Analyze Th17/Treg plasticity data from IBD papers for statistical conversion rates"

Research Agent → searchPapers('Th17 Treg plasticity IBD') → Analysis Agent → readPaperContent(Ueno 2015) + runPythonAnalysis(pandas on FOXP3 loss metrics) → matplotlib plot of conversion probabilities.

"Draft LaTeX review on Treg homing mechanisms with citations from top papers"

Synthesis Agent → gap detection('Treg α4β7 homing') → Writing Agent → latexEditText(protocol summary) → latexSyncCitations(Desreumaux 2012, Fischer 2015) → latexCompile → PDF with integrated bibliography.

"Find code for Treg expansion simulations in GitHub from recent papers"

Research Agent → paperExtractUrls(Esensten 2018) → paperFindGithubRepo → Code Discovery → githubRepoInspect → exportCsv of simulation parameters for runPythonAnalysis replication.

Automated Workflows

Deep Research workflow scans 50+ papers on 'Treg therapy autoimmunity' via searchPapers → citationGraph → structured report with GRADE-scored efficacy from Desreumaux (2012). DeepScan applies 7-step CoVe to verify homing claims in Fischer (2015) vs. Sun (2019). Theorizer generates hypotheses on integrin-targeted Treg engineering from Neurath (2013) and Ueno (2015).

Frequently Asked Questions

What defines T Regulatory Cell Therapy?

It involves ex vivo expansion of CD4+CD25+FOXP3+ Tregs for adoptive transfer to restore immune tolerance (Esensten et al., 2018).

What are key methods in Treg therapy?

Antigen-specific expansion (Desreumaux et al., 2012) and integrin-mediated homing enhancement (Fischer et al., 2015) are core; α4β7 blockade risks Treg impairment (Sun et al., 2019).

What are seminal papers?

Desreumaux et al. (2012, 370 citations) showed safety in Crohn's; Edozie et al. (2014, 73 citations) detailed transplant tolerance protocols.

What open problems exist?

Treg instability to Th17 (Ueno, 2015), homing specificity (Fischer et al., 2015), and scalable GMP production (Alexander and Greco, 2022) persist.

Research Immunodeficiency and Autoimmune Disorders with AI

PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:

Start Researching T Regulatory Cell Therapy with AI

Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.